Investigating how endocrine disruptors affect gut bacteria and colorectal cancer risk
Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development
This study is trying to see if certain chemicals that mess with hormones can change gut bacteria and increase the risk of colorectal cancer in people.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Poitiers University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT06809660 on ClinicalTrials.gov |
What this trial studies
This study examines the relationship between endocrine disruptors and colorectal cancer by comparing gut microbiota in patients with colorectal cancer to those without. It involves collecting stool, hair, and urine samples from 200 participants, divided into two groups of 100. Participants will complete a questionnaire regarding their exposure to endocrine disruptors, and routine care data will be collected over five years. The goal is to identify specific endocrine disruptors linked to dysbiosis and colorectal cancer development.
Who should consider this trial
Good fit: Ideal candidates include individuals scheduled for endoscopy who are either diagnosed with colorectal cancer or are suspected to be free of it.
Not a fit: Patients with hereditary colorectal cancer or those undergoing treatment for chronic inflammatory bowel disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of environmental factors contributing to colorectal cancer, potentially leading to improved prevention strategies.
How similar studies have performed: While the specific focus on endocrine disruptors and gut microbiota in colorectal cancer is novel, related studies have shown the impact of environmental factors on cancer risk.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled endoscopy during the inclusion visit or within 18 months following this consultation. * Signed consent from the patient after clear and fair information about the study is provided. * Patient is free of guardianship, curatorship, or dependency. * Patient is covered by a social security system or through a third party. Exclusion Criteria: * Patients receiving treatment for chronic inflammatory bowel disease; * Patients with hereditary colorectal cancer; * Use of antibiotics, probiotics, or prebiotics within four weeks prior to stool sample collection; * Patients who have undergone neoadjuvant chemotherapy or radiotherapy; * Patients who have had previous surgical resection; * Patients under enhanced protection: minors, individuals deprived of liberty by judicial or administrative decision, individuals residing in healthcare or social institutions, and adults under legal protection; * Pregnant and/or breastfeeding women. Exclusion Criteria During Study Participation: * Patients presenting any of the following during their participation in the study will be excluded: * Use of antibiotics, probiotics, or prebiotics before stool collection (between inclusion and stool collection, which may occur within the month); * Endoscopy not performed within 18 months following inclusion; * Failure to send/receive stool samples
Where this trial is running
Poitiers
- CHU de Poitiers — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Violaine RANDRIAN, Doctor
- Email: violaine.randrian@chu-poitiers.fr
- Phone: 00335 49 44 42 93
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.